US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

17.35

+0.09000.52%

Volume:421.00

Turnover:7.22K

Market Cap:5.87B

PE:193.89

High:17.35

Open:17.35

Low:17.35

Close:17.26

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Reports Record FY2024 Results and Sets Ambitious FY2025 Growth Targets

Telix Pharmaceuticals Reports Robust Financial Growth in 2024

Telix Pharmaceuticals’ Illuccix Approved in UK, Enhancing Prostate Cancer Management

Is Telix Pharmaceuticals Limited (TLX) the Best Long Term ASX Stock to Buy Now?

Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)

Telix Pharmaceuticals Compeletes Acquisition of US-Based Biotech Company; Shares Hit All-Time High

MT Newswires Live

Telix Pharmaceuticals Announces Quotation of New Securities

Telix Pharmaceuticals Expands Pipeline with ImaginAb Acquisition

Buy Rating for Telix Pharmaceuticals Ltd. Supported by Strong Financials and Growth Potential

Telix Pharmaceuticals Completes Acquisition of RLS

MT Newswires Live

UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating

MT Newswires Live

Telix Pharmaceuticals Receives Positive Decision on Marketing Application in Europe; Shares Hit All-Time High

MT Newswires Live

Telix Pharmaceuticals Secures Marketing Approval for Illuccix in Europe

MT Newswires Live

Illuccix® Receives European Approval

Telix Pharmaceuticals’ Illuccix Gains European Marketing Authorization

Telix Pharmaceuticals (TLX) Shares Soar on FY24 Success

Telix Pharmaceuticals' Revenue Surges 46% in Q4; Full-Year Revenue Beats Guidance

MT Newswires Live

Telix Pharmaceuticals to Acquire Assets of ImaginAb for $45 Million

MT Newswires Live

Telix Pharma Reported Q4 Revenue Of $142M, Up 46% YoY, FY24 Revenue Of $517M, Up By 55% YoY

Telix Exceeds FY24 Guidance with US$142M Q4 Revenue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TLX/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":17.35,"timestamp":1749648861627,"preClose":17.26,"halted":0,"volume":421,"delay":0,"floatShares":275137421,"shares":338109048,"eps":0.089486,"marketStatus":"Trading","change":0.09,"latestTime":"06-11 09:38:11 EDT","open":17.35,"high":17.35,"low":17.35,"amount":7221.9059910000005,"amplitude":0,"askPrice":17.5,"askSize":600,"bidPrice":17,"bidSize":10,"shortable":3,"etf":0,"ttmEps":0.089486,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1749672000000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":17.26,"preHourTrading":{"tag":"盘前","latestPrice":17.26,"preClose":17.26,"latestTime":"08:14 EDT","volume":2,"amount":35.370002,"timestamp":1749644047154},"postHourTrading":{"tag":"盘后","latestPrice":17.27,"preClose":17.27,"latestTime":"16:04 EDT","volume":1,"amount":17.29,"timestamp":1749585843647},"volumeRatio":1.460471},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":275137421,"roa":"5.33%","roe":"13.92%","lyrEps":0.093266,"volumeRatio":1.460471,"shares":338109048,"dividePrice":0,"high":17.35,"amplitude":0,"preClose":17.26,"low":17.35,"week52Low":13.61,"pbRate":"15.85","psRate":"11.50","week52High":30.36,"institutionHeld":0,"latestPrice":17.35,"committee":-0.967213,"eps":0.089486,"divideRate":0,"volume":421,"delay":0,"ttmEps":0.089486,"open":17.35,"prevYearClose":15.4,"prevWeekClose":16.77,"prevMonthClose":16.9899,"prevQuarterClose":16.76,"fiveDayClose":17.48,"twentyDayClose":16.71,"sixtyDayClose":17.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512989418","title":"Telix Pharmaceuticals Reports Record FY2024 Results and Sets Ambitious FY2025 Growth Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2512989418","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512989418?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:17","pubTimestamp":1740039444,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ). Telix Pharmaceuticals reported a record financial performance for FY2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-record-fy2024-results-and-sets-ambitious-fy2025-growth-targets?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-record-fy2024-results-and-sets-ambitious-fy2025-growth-targets?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2512418928","title":"Telix Pharmaceuticals Reports Robust Financial Growth in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2512418928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512418928?lang=en_us&edition=fundamental","pubTime":"2025-02-20 16:17","pubTimestamp":1740039431,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) just unveiled an announcement. Telix Pharmaceuticals Ltd. announced its financial results for the fiscal y...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-robust-financial-growth-in-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-reports-robust-financial-growth-in-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2511538562","title":"Telix Pharmaceuticals’ Illuccix Approved in UK, Enhancing Prostate Cancer Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2511538562","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511538562?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:27","pubTimestamp":1739395653,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has shared an announcement. Telix Pharmaceuticals announced that its prostate cancer imaging agent, Illucc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-illuccix-approved-in-uk-enhancing-prostate-cancer-management?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-illuccix-approved-in-uk-enhancing-prostate-cancer-management?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2510323343","title":"Is Telix Pharmaceuticals Limited (TLX) the Best Long Term ASX Stock to Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2510323343","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510323343?lang=en_us&edition=fundamental","pubTime":"2025-02-12 00:47","pubTimestamp":1739292442,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now.In this article, we are going to take a look at where Telix Pharmaceuticals Limited stands against the other long term ASX stocks.Vanguard believes that Australia's economy remains well-placed to recover gradually in 2025 after the broader economy witnessed its slowest growth in 32 years in 2024 amid sticky inflation and higher interest rates. The investment firm expects modest improvement in economic momentum, courtesy of higher real household incomes as inflation subsides. Furthermore, a rebounding housing market and expectations of rate cuts might also provide some support.Key Indicators Likely to Shape Australia's Economy in 2025. The Reserve Bank of Australia  kept the policy rate target unchanged at 4.35% on December 10. However, the bank noted that it continues to see signs of inflation moving sustainably towards the target. That being said, Vanguard expects that RBA will remain patient and that a tight l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/telix-pharmaceuticals-limited-tlx-best-164722104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["TSYW.SI","XJO.AU","MNQmain","LU1303367103.USD","QLD","SQQQ","LU0757428866.USD","BK4139","TLX.AU","LU1815336091.USD","NQmain","BK4137","XKO.AU","BLA.AU",".IXIC","LU2098885051.SGD","BK7067","USAW.SI","USJW.SI","TLX","QID","XAO.AU","RBA","NVIW.SI","PSQ","TQQQ"],"gpt_icon":1},{"id":"2508845365","title":"Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals Ltd. (OtherTLPPF) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508845365","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508845365?lang=en_us&edition=fundamental","pubTime":"2025-02-04 20:20","pubTimestamp":1738671650,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Telix Pharmaceuticals Ltd. (TLPPF – Research Report) and Fisher &...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-telix-pharmaceuticals-ltd-othertlppf-and-fisher-paykel-healthcare-corporation-limited-otherfspkf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-telix-pharmaceuticals-ltd-othertlppf-and-fisher-paykel-healthcare-corporation-limited-otherfspkf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","TLX","HCSG","BK4139"],"gpt_icon":0},{"id":"2507988160","title":"Telix Pharmaceuticals Compeletes Acquisition of US-Based Biotech Company; Shares Hit All-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=2507988160","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507988160?lang=en_us&edition=fundamental","pubTime":"2025-01-31 09:07","pubTimestamp":1738285621,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  completed the acquisition of US-based biotechnology company ImaginAb for an upfront consideration of $45 million, according to a Friday filing with the Australian bourse.The company paid $10 million in cash and $31 million in equity through the issue of about 2.1 million shares, with a deferred payment of up to $4 million in equity at the end of a 15-month indemnity period, the filing said.The company will pay up to $185 million upon achieving key development and commercial milestones, per the filing.Shares rose 1% in morning trade Friday and earlier reached an all-time high.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU","BK7067"],"gpt_icon":0},{"id":"2507040326","title":"Telix Pharmaceuticals Announces Quotation of New Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2507040326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507040326?lang=en_us&edition=fundamental","pubTime":"2025-01-31 07:18","pubTimestamp":1738279087,"startTime":"0","endTime":"0","summary":"An update from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) is now available. Telix Pharmaceuticals Ltd. has announced the quotation of 2,053,311 new o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-quotation-of-new-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-announces-quotation-of-new-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2507604064","title":"Telix Pharmaceuticals Expands Pipeline with ImaginAb Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2507604064","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507604064?lang=en_us&edition=fundamental","pubTime":"2025-01-31 07:09","pubTimestamp":1738278574,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has completed the acquisition of assets from ImaginAb, I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-expands-pipeline-with-imaginab-acquisition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-expands-pipeline-with-imaginab-acquisition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2507687587","title":"Buy Rating for Telix Pharmaceuticals Ltd. Supported by Strong Financials and Growth Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2507687587","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507687587?lang=en_us&edition=fundamental","pubTime":"2025-01-29 20:07","pubTimestamp":1738152429,"startTime":"0","endTime":"0","summary":"In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-telix-pharmaceuticals-ltd-supported-by-strong-financials-and-growth-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-telix-pharmaceuticals-ltd-supported-by-strong-financials-and-growth-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX"],"gpt_icon":0},{"id":"2506668539","title":"Telix Pharmaceuticals Completes Acquisition of RLS","url":"https://stock-news.laohu8.com/highlight/detail?id=2506668539","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506668539?lang=en_us&edition=fundamental","pubTime":"2025-01-28 07:14","pubTimestamp":1738019671,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) completed its acquisition of US radiopharmacy network RLS for an upfront cash payment of $230 million and a deferred payment of $20 million, according to a Tuesday fili","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067","TLX"],"gpt_icon":0},{"id":"2506740393","title":"UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2506740393","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506740393?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:19","pubTimestamp":1737983944,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) has an average rating of overweight and mean price target of $16.70, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"gpt_icon":0},{"id":"2504978365","title":"Telix Pharmaceuticals Receives Positive Decision on Marketing Application in Europe; Shares Hit All-Time High","url":"https://stock-news.laohu8.com/highlight/detail?id=2504978365","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504978365?lang=en_us&edition=fundamental","pubTime":"2025-01-17 08:27","pubTimestamp":1737073626,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  received a positive decision on its marketing authorization application in Europe for its imaging product, Illuccix, used in a positron emission tomography scan to detect prostate cancer, according to a Friday filing with the Australian bourse.The German Federal Institute for Drugs and Medical Devices, issued a final assessment report, confirming that Illuccix should receive marketing authorization from the reference member state and all 18 European Economic Area concerned member states, the filing said.The regulatory process will now transition into an administrative national phase for commercial launch in each country, according to the filing.Shares rose 3% in morning trade Friday and earlier hit an all-time high.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2504921224","title":"Telix Pharmaceuticals Secures Marketing Approval for Illuccix in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2504921224","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504921224?lang=en_us&edition=fundamental","pubTime":"2025-01-17 07:03","pubTimestamp":1737068608,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Thursday it received a positive decision on its marketing authorization application for Illuccix, its prostate cancer positron emission tomography imaging agent, in Europe.The application was submitted via a decentralized procedure, with the German Federal Institute for Drugs and Medical Devices acting as the reference member state. The RMS and all 18 European Economic Area Concerned Member States have agreed that Illuccix should receive marketing authorization.This decision sets the stage for the administrative national phase, where authorizations will be finalized to facilitate the commercial launch of Illuccix across the region.Once launched, Illuccix will enable the detection of prostate-specific membrane antigen-positive lesions with PET imaging in adults with prostate cancer, according to the company.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU","BK7067","BK4139"],"gpt_icon":0},{"id":"2504263999","title":"Illuccix® Receives European Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2504263999","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504263999?lang=en_us&edition=fundamental","pubTime":"2025-01-17 06:06","pubTimestamp":1737065160,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and LIGE, Belgium, Jan.  17, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/16/3011183/0/en/Illuccix-Receives-European-Approval.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAA","LU1894683348.USD","BK4139","CMS","BK4208","BCR","ASX","BK4084","BK4533","BK4217","BK4543","LU2637428348.USD","BK4144","TLX","BK4215","LU2346227817.USD","BK4526","BK4585","BK4213","LU1894683264.USD","TGA","BK4141","BK4588","EEA","DCP","PSA"],"gpt_icon":0},{"id":"2504925644","title":"Telix Pharmaceuticals’ Illuccix Gains European Marketing Authorization","url":"https://stock-news.laohu8.com/highlight/detail?id=2504925644","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504925644?lang=en_us&edition=fundamental","pubTime":"2025-01-17 05:51","pubTimestamp":1737064277,"startTime":"0","endTime":"0","summary":"An announcement from Telix Pharmaceuticals Ltd. ( ($AU:TLX) ) is now available. Telix Pharmaceuticals has announced that its prostate cancer PET im...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-illuccix-gains-european-marketing-authorization?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-illuccix-gains-european-marketing-authorization?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2503259098","title":"Telix Pharmaceuticals (TLX) Shares Soar on FY24 Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2503259098","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503259098?lang=en_us&edition=fundamental","pubTime":"2025-01-14 13:49","pubTimestamp":1736833778,"startTime":"0","endTime":"0","summary":"Shares of the ASX-listed Telix Pharmaceuticals Limited ($AU:TLX) soared 4% today after the company impressed investors with successful results in F...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/telix-pharmaceuticals-tlx-shares-soar-on-fy24-success?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/telix-pharmaceuticals-tlx-shares-soar-on-fy24-success?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2503556623","title":"Telix Pharmaceuticals' Revenue Surges 46% in Q4; Full-Year Revenue Beats Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2503556623","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503556623?lang=en_us&edition=fundamental","pubTime":"2025-01-14 05:43","pubTimestamp":1736804582,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) reported unaudited revenue of roughly $142 million for the fourth quarter of 2024, an increase of 46% from the year-earlier period's $97 million, according to a Monday ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","TLX.AU"],"gpt_icon":0},{"id":"2503796327","title":"Telix Pharmaceuticals to Acquire Assets of ImaginAb for $45 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2503796327","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503796327?lang=en_us&edition=fundamental","pubTime":"2025-01-13 16:47","pubTimestamp":1736758053,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said Sunday it has agreed to purchase a pipeline of drug candidates, a proprietary biologics technology platform, and a protein engineering and discovery research facility from ImaginAb for $45 million in cash and stock plus future milestone, royalty, and sublicense payments.Under the deal, Telix said it will pay $10 million in cash and $31 million in stock at closing and $4 million in stock after 15 months.In addition, it will pay up to $185 million in payments upon achievement of certain development and commercial milestones, as well as royalties and sublicense fees in the low single digits, the company said,The early-stage cancer drug candidates acquired use \"small engineered antibody formats that enable highly specific cancer targeting, combined with fast tumor uptake and blood clearance,\" the company said.The acquisition also includes a research facility in California already staffed by a team of experts, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","TLX","TLX.AU"],"gpt_icon":0},{"id":"2503263653","title":"Telix Pharma Reported Q4 Revenue Of $142M, Up 46% YoY, FY24 Revenue Of $517M, Up By 55% YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2503263653","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503263653?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:19","pubTimestamp":1736752774,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).Sustained revenue growthQ4","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/01/42937843/telix-pharma-reported-q4-revenue-of-142m-up-46-yoy-fy24-revenue-of-517m-up-by-55-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX"],"gpt_icon":0},{"id":"2503325978","title":"Telix Exceeds FY24 Guidance with US$142M Q4 Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2503325978","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503325978?lang=en_us&edition=fundamental","pubTime":"2025-01-13 15:08","pubTimestamp":1736752080,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Jan.  13, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today provides an update on its commercial and oper","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008122/0/en/Telix-Exceeds-FY24-Guidance-with-US-142M-Q4-Revenue.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4205","ASX","BK4543","BK4139","UK","TLX","USA","BK4528","BK4526","TGA","BK4141","BK4233"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":116,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6667,"buy":0.3333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6667,"analysts":3,"updateTime":1749182400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-06-10","current":175.966527,"percent":0.468085,"low":151.061716,"twenty":167.889662,"median":176.979518,"eighty":187.777645,"high":205.576265,"avg":177.771034,"sd":12.409411,"marketCap":5728494239.6},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-10","current":175.966527,"twenty":167.889662,"median":176.979518,"eighty":187.777645,"marketCap":5728494239.6}],"updateTime":1749630900225}}}